Mammary Cell News Volume 11.20 | May 30 2019

TOP STORY

Atypical Function of a Centrosomal Module in WNT Signaling Drives Contextual Cancer Cell Motility

Upon exosome mobilization of PCP-proteins, the authors showed that DVL2 orchestrated recruitment of a CEP192-PLK4/AURKB complex to the cell cortex where PLK4/AURKB act redundantly to drive protrusive activity and cell motility. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

SORLA Regulates Endosomal Trafficking and Oncogenic Fitness of HER2

Scientists found that sortilin-related receptor 1 (SORLA) co-precipitated with human epidermal growth factor receptor 2 (HER2) in cancer cells and regulated HER2 subcellular distribution by promoting recycling of the endosomal receptor back to the plasma membrane. [Nat Commun] Full Article

Mitohormesis Primes Tumor Invasion and Metastasis

Investigators showed that mitohormesis primed a subpopulation of cancer cells to basally upregulate mitochondrial stress responses, such as the mitochondrial unfolded protein response providing an adaptive metastatic advantage. [Cell Rep] Full Article | Graphical Abstract

The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer

Integrated genomic and immune landscapes showed that metastases propagated and evolved as communities of clones, revealed their predicted neo-antigen landscapes, and showed that they could accumulate HLA loss of heterozygosity. [Cell Rep] Full Article | Graphical Abstract

Leptin Produced by Obesity-Altered Adipose Stem Cells Promotes Metastasis but Not Tumorigenesis of Triple-Negative Breast Cancer in Orthotopic Xenograft and Patient-Derived Xenograft Models

Obesity-altered adipose stem cells (obASCs) were used to evaluate obesity-mediated effects of triple-negative breast cancer (TNBC). Both in vitro and in vivo analyses of TNBC cell lines were co-cultured with six pooled donors of obASCs or ASCs isolated from lean women. [Breast Cancer Res] Full Article

Metabolic Reprograming via Silencing of Mitochondrial VDAC1 Expression Encourages Differentiation of Cancer Cells

Researchers compared the effects of down-regulated voltage-dependent anion channel 1 (VDAC1) expression in the U-87MG glioblastoma, MDA-MB-231 triple negative breast cancer and A549 lung cancer cell lines using si-RNA specific to human VDAC1. [Mol Ther Nucleic Acids] Abstract | Full Article

Translational Downregulation of Twist1 Expression by Antiproliferative Gene, B-Cell Translocation Gene 2, in the Triple Negative Breast Cancer Cells

Scientists investigated molecular mechanisms of BTG2^/TIS21-inhibited Twist1 translation in triple negative breast cancer cells and in vivo BTG2^/TIS21-knockout mice and human breast cancer tissues. [Cell Death Dis] Full Article

Mitochondrial ncRNA Targeting Induces Cell Cycle Arrest and Tumor Growth Inhibition of MDA-MB-231 Breast Cancer Cells through Reduction of Key Cell Cycle Progression Factors

Investigators showed that sntisense long noncoding mitochondrial RNA knockdown induced cell death preceded by proliferative blockage in three different human breast cancer cell lines. This effect is mediated by downregulation of the key cell cycle progression factors cyclin B1, cyclin D1, CDK1, CDK4, and survivin. [Cell Death Dis] Full Article

Interleukin-32θ Inhibits Tumor-Promoting Effects of Macrophage-Secreted CCL18 in Breast Cancer

In MDA-MB-231 cells, interleukin-32θ overexpression attenuated migration, invasion, tumor-promoting factors, and increased epithelial markers levels upon treatment with conditioned media from THP-1-derived macrophages. [Cell Commun Signal] Full Article

Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News.

Epigenetic Reprogramming of TGF-β Signaling in Breast Cancer

The authors focus on recent advances relating to how epigenetic changes such as acetylation and methylation control the outcome of transforming growth factor-β (TGF-β) signaling and alter the fate of breast cancer cells. [Cancers] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Athenex to Present at the 2019 ASCO Annual Meeting

Athenex, Inc. announced that it will present data and exhibit at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. [Press release from Athenex, Inc. discussing research to be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release

CELLSEARCH Studies Show Potential Predictive Role for Circulating Tumor Cells in Metastatic Breast Cancer

Menarini Silicon Biosystems announced that two studies using the company’s CELLSEARCH^® circulating tumor cell test provided preliminary insight into the impact of liquid biopsy on metastases and prognosis for patients with metastatic breast cancer. [Press release from Menarini Silicon Biosystems (PR Newswire Association LLC) discussing research to be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release

Sermonix Receives FDA Fast Track Designation for Investigational Drug Lasofoxifene

Sermonix Pharmaceuticals LLC announced that its lead investigational drug, lasofoxifene, has been granted Fast Track designation by the FDA. Sermonix is currently engaged in a Phase II clinical study of lasofoxifene in estrogen receptor-positive metastatic breast cancer. [Sermonix Pharmaceuticals LLC] Press Release

FDA Approves Novartis Piqray^® – the First and Only Treatment Specifically for Patients with a PIK3CA Mutation in HR⁺/HER2^– Advanced Breast Cancer

Novartis announced the FDA has approved Piqray^® in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR⁺/HER2^–), PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test following progression on or after an endocrine-based regimen. [Novartis AG] Press Release

Here’s Why the Outcomes of This Week’s European Elections Are Good News for Science

Although populist and euroskeptic parties grew in last week’s elections for the European Parliament, the tsunami that EU supporters feared didn’t happen. That comes as a relief to many scientists, because several of the populist movements now on the rise in Europe appear to have little interest in science, flirt with antiscientific ideas, or have tried to curtail academic freedom. [ScienceInsider] Editorial

White House Sends Mixed Messages on 2020 Research Spending Bills

President Donald Trump doesn’t want Congress to boost the budgets of the National Institutes of Health or the National Science Foundation. But he has no objection to giving more research dollars to parts of the Department of Energy and NASA. [ScienceInsider] Editorial

NEW Cell Symposia: Hallmarks of Cancer
November 17-19, 2019
Seattle, Washington, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellow or Research Scientist – Cancer Biology (Icahn School of Medicine at Mount Sinai)

Postdoctoral Associate – Immune Responses (The Jackson Laboratory)

Postdoctoral Fellows – Bioinformatics (IRCCS European Institute of Oncology)

Postdoctoral Fellowship – PcG-Mediated Mechanisms in Breast Cancer (University of Miami)

Postdoctoral Research Position – Molecular Biology & Cancer Research (Augusta University)

Postdoctoral Fellowship – Tumor Suppressor CSMD1 (Lund University)

Postdoctoral Position – Breast Cancer Research (Massachusetts General/Harvard Medical School)

Faculty Position – Breast and Ovarian Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Associate – Cancer Immunology (The Jackson Laboratory)

Postdoctoral Fellow – Cancer Bioinformatics (BC Cancer Research Center, PHSA)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.